Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Knight Therapeutics Inc (GUD) Common Stock NPV

Sell:7.56 CAD Buy:7.60 CAD Change: 0.17 CAD (2.30%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
Sell:7.56 CAD
Buy:7.60 CAD
Change: 0.17 CAD (2.30%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
Sell:7.56 CAD
Buy:7.60 CAD
Change: 0.17 CAD (2.30%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

Contact details

Address:
3400 De Maisonneuve Blvd W
MONTREAL
H3Z 3B8
Canada
Telephone:
+1 (514) 4844483
Website:
https://www.gud-knight.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GUD
ISIN:
CA4990531069
Market cap:
1.03 billion CAD
Shares in issue:
135.96 million
Sector:
Pharmaceuticals
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • James Gale
    Independent Chairman of the Board
  • Samira Sakhia
    President, Chief Financial Officer, Director
  • Jonathan Goodman
    Chief Executive Officer, Director
  • Amal Khouri
    Vice President - Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.